Australia markets open in 4 hours 13 minutes

Almirall, S.A. (ALME.XC)

Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
9.660.00 (0.00%)
At close: 02:43PM BST
Full screen
Previous close9.66
Open9.66
Bid9.32 x N/A
Ask9.45 x N/A
Day's range9.66 - 9.66
52-week range8.03 - 9.66
Volume66
Avg. volume45
Market cap2.06B
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.18 (1.91%)
Ex-dividend date17 May 2024
1y target estN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).